用于治疗心血管疾病的基于的纳米药物的进展:机制,当前趋势和前景
Ping Li1,2,3, Shibing Wang4, Huafeng Shou5
1College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Nanomedicine (London, England)
|August 6, 2025
概括
纳米颗粒由于其抗氧化和抗炎作用,显示出治疗心血管疾病的前景. 进一步的研究将优化它们的设计,以提高有针对性的输送和治疗疗效.
科学领域:
- 纳米医学是一种纳米医学.
- 心脏病学 心脏病学
- 材料科学 材料科学 材料科学
背景情况:
- 心血管疾病是全球主要的健康负担.
- 纳米颗粒提供独特的抗氧化,抗炎和心脏保护性质.
- 这些纳米粒子正在被探索为先进的药物输送系统.
研究的目的:
- 审查纳米颗粒在心血管疾病中的治疗潜力.
- 探索在相关的炎症和代谢条件中的应用.
- 确定纳米粒子治疗开发的挑战和最近的进展.
主要方法:
- 在PubMed,Scopus和Web of Science (2010-2024) 的综合文献搜索.
- 对纳米粒子特性和治疗应用的研究分析.
- 对功能化策略和融入生物相容支架的审查.
主要成果:
- 纳米颗粒显示出对心血管疾病管理的巨大潜力.
- 应用范围扩展到类风湿性关节炎,喘,炎症性肠病,牛皮,癌症,糖尿病,NAFLD和传染病.
- 关键的挑战包括目标识别和功能化,以确保稳定性和有针对性的交付.
结论:
- 纳米粒子是多功能纳米平台,具有用于心血管治疗的高临床翻译潜力.
- 功能化和支架集成方面的进展是有希望的.
- 进一步的研究对于优化设计和理解作用机制至关重要.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Heart Failure Drugs: Inotropic Agents
724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


